Book Value per Share: Spruce Biosciences Inc. (SPRB)

Graphic logo of Spruce Biosciences (SPRB)

Spruce Biosciences develops drugs for rare metabolic disorders, leveraging patent protection against competition. Orphan drug status allows the company to set premium pricing for insurance providers. The brand is currently regaining investor confidence following clinical trials. The book value forecast per share illustrates net capital dynamics, and 30.23 determines the current status of the parameter on the chart.

sprucebiosciences.com (SPRB): Share Book Value from 07/04/2022 to 10/27/2026

sprucebiosciences.com - analytical breakdowns and key metrics (SPRB)

- price and consensus price forecast:
Price Chart Spruce Biosciences|SPRB - Fair Value Consensus
- market capitalization data:
Market Capitalization Spruce Biosciences, Inc.|SPRB - Total Company Value
- book capitalization data:
Net Assets per Single Share Spruce Biosciences|SPRB - Net Asset Value|Market Capitalization to Book Value Ratio sprucebiosciences.com|SPRB - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Spruce Biosciences|SPRB - Long-Term Debt to Capital|Short-Term Debt to Equity Spruce Biosciences, Inc.|SPRB - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Spruce Biosciences, Inc.
Fundamental company valuation:Spruce Biosciences - SPRB
Manufactured products of Spruce Biosciences, Inc.

Book value per share determines the portion of net assets attributable to a single security, allowing for an assessment of the issuer's actual asset backing net of liabilities. By analyzing the final book value per share, an investor can see the financial foundation of Spruce Biosciences (SPRB), which supports the development of unique drugs against adrenal hyperplasia, creating a basis for future pricing power and margin protection.

Competitors of Spruce Biosciences (SPRB)

Net Assets per Single Share Ascendis Pharma Inc. (ASND)|MDGL - Accounting Value of a Share|Corcept Therapeutics (CORT) - Book Value per Share|RYTM (rhythmtx.com) - Net Assets per Single Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share Crinetics Corp (CRNX)|Book Value per Share NAMS (NewAmsterdam Pharma)|soleno.life - Book Value per Share|Net Assets per Single Share Amicus Therapeutics, Inc. (FOLD)|ETNB: Accounting Value of a Share|AGIO (Agios Pharmaceuticals Inc) - Net Assets per Single Share|Structure Corp (GPCR) - Accounting Value per Share|MDXG (MiMedx Group, Inc.) - Book Value per Share|Book Value per Share rezolutebio.com (RZLT)|Lexicon Pharmaceuticals, Inc. (LXRX) - Accounting Value per Share|Accounting Value of a Share MBX (MBX Biosciences, Inc.)|Altimmune Corp - Net Assets per Single Share|Accounting Value per Share Aardvark Pharma AARD|SGMT (Sagimet Biosciences) - Book Value per Share|bioagelabs.com (BIOA) - Net Asset Value per Share|BMEA - Accounting Value per Share|Quince Therapeutics, Inc. (QNCX) - Book Price of a Share|GUTS (Fractyl) - Book Value per Share|Book Value per Share vTv Therapeutics Inc|Book Value per Share Agape ATP Corporation (ATPC)|Net Assets per Single Share PLUR (pluri-biotech.com)|SYBX: Net Assets per Single Share|Lipocine Inc - Net Asset Value per Share|MTNB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS